全文获取类型
收费全文 | 9759篇 |
免费 | 482篇 |
国内免费 | 112篇 |
专业分类
耳鼻咽喉 | 43篇 |
儿科学 | 220篇 |
妇产科学 | 296篇 |
基础医学 | 1069篇 |
口腔科学 | 130篇 |
临床医学 | 716篇 |
内科学 | 2457篇 |
皮肤病学 | 274篇 |
神经病学 | 947篇 |
特种医学 | 400篇 |
外科学 | 1816篇 |
综合类 | 23篇 |
一般理论 | 1篇 |
预防医学 | 275篇 |
眼科学 | 137篇 |
药学 | 615篇 |
中国医学 | 25篇 |
肿瘤学 | 909篇 |
出版年
2023年 | 68篇 |
2022年 | 82篇 |
2021年 | 247篇 |
2020年 | 184篇 |
2019年 | 212篇 |
2018年 | 283篇 |
2017年 | 195篇 |
2016年 | 262篇 |
2015年 | 330篇 |
2014年 | 417篇 |
2013年 | 548篇 |
2012年 | 837篇 |
2011年 | 802篇 |
2010年 | 533篇 |
2009年 | 431篇 |
2008年 | 699篇 |
2007年 | 700篇 |
2006年 | 630篇 |
2005年 | 621篇 |
2004年 | 585篇 |
2003年 | 470篇 |
2002年 | 447篇 |
2001年 | 43篇 |
2000年 | 39篇 |
1999年 | 42篇 |
1998年 | 74篇 |
1997年 | 47篇 |
1996年 | 49篇 |
1995年 | 54篇 |
1994年 | 59篇 |
1993年 | 42篇 |
1992年 | 38篇 |
1991年 | 39篇 |
1990年 | 32篇 |
1989年 | 19篇 |
1988年 | 20篇 |
1987年 | 16篇 |
1986年 | 13篇 |
1985年 | 11篇 |
1984年 | 21篇 |
1983年 | 19篇 |
1982年 | 9篇 |
1981年 | 9篇 |
1980年 | 11篇 |
1979年 | 6篇 |
1978年 | 8篇 |
1977年 | 7篇 |
1975年 | 4篇 |
1928年 | 3篇 |
1926年 | 3篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
2.
Alessandro Rambaldi Alessandra Iurlo Alessandro M. Vannucchi Bruno Martino Attilio Guarini Marco Ruggeri Nikolas von Bubnoff Marianna De Muro Mary Frances McMullin Stefania Luciani Vincenzo Martinelli Axel Nogai Vittorio Rosti Alessandra Ricco Paolo Bettica Sara Manzoni Silvia Di Tollo 《Blood cancer journal》2021,11(3)
3.
Fiore Manganelli Silvia Parisi Maria Nolano Francesco Miceli Stefano Tozza Chiara Pisciotta Rosa Iodice Vincenzo Provitera Rita Cicatiello Stephan Zuchner Maurizio Taglialatela Tommaso Russo Lucio Santoro 《Journal of the peripheral nervous system : JPNS》2019,24(4):330-339
The development of patient‐specific induced pluripotent stem cells (iPSCs) offered interesting insights in modeling the pathogenesis of Charcot‐Marie‐Tooth (CMT) disease and thus we decided to explore the phenotypes of iPSCs derived from a single CMT patient carrying a mutant ATP1A1 allele (p.Pro600Ala). iPSCs clones generated from CMT and control fibroblasts, were induced to differentiate into neural precursors and then into post‐mitotic neurons. Control iPSCs differentiated into neuronal precursors and then into post‐mitotic neurons within 6‐8 days. On the contrary, the differentiation of CMT iPSCs was clearly defective. Electrophysiological properties confirmed that post‐mitotic neurons were less mature compared to the normal counterpart. The impairment of in vitro differentiation of CMT iPSCs only concerned with the neuronal pathway, because they were able to differentiate into mesendodermal cells and other ectodermal derivatives. ATP1A1 was undetectable in the few neuronal cells derived from CMT iPSCs. ATP1A1 gene mutation (p.Pro600Ala), responsible for a form of axonal CMT disease, is associated in vitro with a dramatic alteration of the differentiation of patient‐derived iPSCs into post‐mitotic neurons. Thus, the defect in neuronal cell development might lead in vivo to a decreased number of mature neurons in ATP1A1‐CMT disease. 相似文献
4.
5.
6.
Filippo Pietrantonio Christian Cotsoglou Giovanni Fucà Salvatore Lo Vullo Federico Nichetti Massimo Milione Jorgelina Coppa Marta Vaiani Alessandra Alessi Michele Prisciandaro Michele Droz-Dit Busset Federica Morano Salvatore Corallo Silvia Lazzati Maria Antista Alessia Mennitto Giovanni Randon Alessandra Raimondi Vincenzo Mazzaferro 《Clinical colorectal cancer》2019,18(1):34-43.e6
Background
In colorectal cancer liver metastases (CRCLM), bevacizumab-based neoadjuvant strategies provide increased pathologic response. We aimed at assessing the activity of perioperative capecitabine, oxaliplatin, irinotecan, and bevacizumab (COI-B regimen) in patients with potentially resectable CRCLM, and investigating biomarkers for early prediction of pathologic response.Patients and Methods
This was a single-center phase II study enrolling patients with liver-limited, borderline resectable disease and/or high-risk features. Patients received 5 preoperative and 4 postoperative cycles of biweekly COI-B (irinotecan 180 mg/m2 and bevacizumab 5 mg/Kg on day 1, oxaliplatin 85 mg/m2 on day 2, and capecitabine 1000 mg/m2 twice a day on days 2 to 6). The primary endpoint was pathologic response rate in the intention-to-treat population. A Simon 2-stage design was adopted to detect an increase from 30% to 50% with a power of 90%. Dynamic imaging biomarkers (early tumor shrinkage [ETS], deepness of response, maximum standardized uptake volume [SUVmax]/regression index) and next generation sequencing data were explored as surrogates.Results
From June 2013 to March 2017, 46 patients were enrolled. Pathologic response was achieved in 63% patients (endpoint met), and responders achieved significantly better survival outcomes with respect to non-responders. The most frequent grade 3/4 adverse events were diarrhea and neutropenia (8.7%) in the preoperative phase and thromboembolic events (5.9%) in the postoperative phase. ETS and lower SUV-2 were significantly associated with pathologic response.Conclusion
The COI-B regimen is a feasible and highly active perioperative strategy in patients with molecularly unselected, potentially resectable CRCLM. ETS and SUV-2 have a promising role as imaging-based biomarkers for pathologic response. 相似文献7.
8.
Valeria Calcaterra Hellas Cena Elvira Verduci Alessandra Bosetti Gloria Pelizzo Gian Vincenzo Zuccotti 《Nutrients》2020,12(11)
This Special Issue aims to examine the crucial role of nutritional status starting from pregnancy in modulating fetal, neonatal and infant growth and metabolic pathways, with potential long-term impacts on adult health. Poor maternal nutritional conditions in the earliest stages of life during fetal development and early life may induce both short-term and longer lasting effects; in particular, an increased risk of noncommunicable diseases (NCDs) and other chronic diseases such as obesity, which itself is a major risk factor for NCDs, is observed over the lifespan. Poor maternal nutrition affects the fetal developmental schedule, leading to irreversible changes and slowdown in growth. The fetus limits its size to conserve the little energy available for cardiac functions and neuronal development. The organism will retain memory of the early insult, and the adaptive response will result in pathology later on. Epigenetics may contribute to disease manifestation affecting developmental programming. After birth, even though there is a limited evidence base suggesting a relationship between breastfeeding, timing and type of foods used in weaning with disease later in life, nutritional surveillance is also mandatory in infants in the first year of life. We will explore the latest findings on nutrition in early life and term and preterm babies, as well as the role of malnutrition in the short- and long-term impact over the lifespan. Focusing on nutritional interventions represents part of an integrated life-cycle approach to prevent communicable and non-communicable diseases. 相似文献
9.
10.
Annalisa Guida Gwnaël Le Teuff Carolina Alves Emeline Colomba Vincenzo Di Nunno Lisa Derosa Ronan Flippot Bernard Escudier Laurence Albiges 《Oncotarget》2020,11(49):4582
Majority of patients with clear-cell renal cell carcinoma (ccRCC) at first line (1L) treatment are classified in the intermediate-risk (IR) subgroup according to International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) score. As these patients have different prognosis, the aim of this study is to better characterize IR patients in order to better tailor the treatment. Retrospective analysis was performed from IGReCC (Institut Gustave Roussy Renal Cell Carcinoma) database. Overall survival (OS) was defined from start of 1L therapy to death or last follow-up. A multivariable Cox model with backward selection procedure (α = 0.01) and a Classification and Regression Tree (CART) analysis were performed to identify which prognostic factors were associated to OS in IR patients.From 2005 to 2017, 777 patients with ccRCC were treated with an anti-VEGF 1L therapy. Among 571 evaluable patients for IMDC score, 290 (51%) were classified as IR. With median follow-up 5.8 years (min: 0, max: 12.4) 212 deaths (73%) were observed and median OS was 25 months. Only platelet count was significantly associated to OS (hazard ratio 1.88 [95% CI 1.27–2.88] p = 0.0017). Median OS for patients with PLT > UNL was 18 months [95% CI 12–23] versus 29 months [95% CI 21.4–35.7] for patients with normal PLT count. The selection of PLT count was confirmed on bootstrap samples and was also selected for the first split of the CART-tree analysis.Patients in the IR group have a heterogeneous prognosis. Elevated PLT count seems identifies a subgroup of patients with poor outcome in the IMDC intermediate-risk population with ccRCC. 相似文献